INTENSITY
`
`Richard Manning, Ph.D.
`Managing Director
`
`INTENSITY, LLC
`Washington, D.C.
`202.963.4200
`intensity.com
`
`February 2022
`
`Dr. Richard Manning is a Managing Director at Intensity, LLC. He provides data-driven insights
`to help clients solve complex economic problems. He has experience conducting economic
`analyses in matters involving breach of contract, fraud, pricing, economic valuation, intellectual
`property, antitrust, patent infringement, and public policy. His areas of expertise include:
`
` Economic Valuation and Damages
`o Breach of Contract, Fraud, and other Commercial Litigation
`o Intellectual Property
`o Securities Litigation
`Tax, Antitrust and Competition
`
`
`
`
`
`Public Policy
`
`Dr. Manning has testified in U.S. District Court, the Delaware Court of Chancery, and the
`International Chamber of Commerce; served as consulting expert; and prepared reports on
`various matters in the biopharmaceutical and healthcare industries. His career includes 14 years
`as an executive at multinational pharmaceutical companies. He led economic analysis and
`strategy development to shape practices related to emerging business concerns.
`
`Examples of Dr. Manning’s work include:
`
` Economic analysis and strategy relative to challenges affecting pricing, reimbursement,
`and intellectual property protection in worldwide markets.
`
` Collaborating with outside academic economists to analyze critical issues including
`healthcare benefit design; healthcare system reform proposals; marketing and advertising;
`intellectual property protection; FDA regulatory reform, including biosimilars approval
`processes and safety; and new product R&D.
`
`
`
`Specializing in strategic partnerships, merger and acquisitions activity, economic valuation
`of early-stage companies, and other economic analyses for biopharmaceutical, medical
`device, financial, and healthcare clients.
`
`Prior to joining Intensity, Dr. Manning was a Partner with Bates White, an economic consulting
`firm offering analysis and expert testimony services to law firms, Fortune 500 companies, and
`government agencies. Previously, Dr. Manning was Executive Director at Merck & Co., Inc., and
`
`Attachment A-1
`
`Exhibit 2052
`Page 139 of 289
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2001 Page 139
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`CONFIDENTIAL - PROTECTIVE ORDER MATERIAL
`
`

`

`he was Senior Director at Pfizer, Inc. Also, Dr. Manning was a Director in the Advisory Strategy
`Group at PricewaterhouseCoopers.
`
`Dr. Manning was an economics professor at Brigham Young University and a visiting professor
`in the Graduate School of Business at the University of Chicago. As an academic, his teaching
`and research focused on price theory, the economic analysis of law, industrial organization, and
`government regulation economics.
`
`Dr. Manning received his Ph.D. in Economics from the University of Chicago. He earned his B.A.
`in Economics from Brigham Young University.
`
`Education
`
`PhD, Economics, University of Chicago, 1989.
`
`MA, Economics, University of Chicago, 1984.
`
`BA, Economics, Brigham Young University, magna cum laude, 1982.
`
`Professional Experience
`
`Intensity, LLC. Managing Director, 2021 to present.
`
`Bates White Economic Consulting, Washington, DC. Partner, 2012–2021.
`
`Merck & Co., Inc., Whitehouse Station, NJ. Executive Director, 2010–2011.
`
`PricewaterhouseCoopers, LLP, New York, NY. Director, Advisory Strategy, 2008–2010.
`
`Pfizer, Inc., New York, NY. Senior Director, 2003–2008.
`
`Pfizer, Inc., New York, NY. Director, 2000–2003.
`
`Pfizer, Inc., New York, NY. Assistant Director, 1999–2000.
`
`Pfizer, Inc., New York, NY. Manager, 1997–1999.
`
`Department of Economics, Brigham Young University Assistant Professor, 1990–1997.
`
`Graduate School of Business, University of Chicago. Visiting Assistant Professor, 1995–1996.
`
`
` 
`
`CV of Richard Manning, Ph.D.
`
`Page 2
`
`Attachment A-1
`
`Exhibit 2052
`Page 140 of 289
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2001 Page 140
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`CONFIDENTIAL - PROTECTIVE ORDER MATERIAL
`
`

`

`Expert Testimony and Consulting Experience
`Breach of Contract, Fraud, and other Commercial Litigation 
`
`1.
`
`2.
`
`3.
`
`4.
`
`5.
`
`6.
`
`7.
`
`8.
`
`9.
`
`Perrigo v. United States of America. United States District Court, Western District of
`Michigan, Case No. 1:17-cv-00737. Submitted expert report and testified in deposition
`and trial.
`
`Served as expert witness in arbitration before the International Chamber of Commerce
`regarding damages due to an alleged breach of obligations to market a newly launched
`prescription medication. Submitted witness statement, rebuttal statement, and testified
`in hearing.
`
`Merix Pharmaceutical Corp. v. Clinical Supplies Management, Inc. (CSM), United States
`District Court, Northern District of Illinois, Case No. 1:11-cv-03318. Retained as testifying
`expert on behalf of CSM in connection with alleged fraud and breach of contract claims
`related to the performance of a clinical trial for an over-the-counter medication. Authored
`expert report and provided deposition testimony that assessed damages assertions made
`by plaintiff’s experts. Judge Matthew F. Kennelly, of the US District Court for the Northern
`District of Illinois Eastern Division, granted summary judgment on a number of Merix’s
`damages claims. A jury ultimately found in CSM’s favor at trial.
`
`National Union Fire Insurance Company of Pittsburgh, Pennsylvania v. Tyco Integrated
`Security, LLC. United States District Court, Southern District of Florida, Case No. 9:13-
`cv-80371. Authored an expert report and testified on behalf of Tyco regarding damages
`arising from a theft of prescription drugs from a pharmaceutical company warehouse. In
`April 2016, a Florida federal jury found in Tyco’s favor, finding the security company not
`liable in the insurer’s negligence suit.
`
`Elorac v. Sanofi-Aventis Canada. United States District Court, Northern District of Illinois,
`Case No. 1:14-cv-01859. Authored an expert report and provided deposition testimony
`assessing damages in a breach of contract federal district court action on behalf of the
`plaintiff, asserting that the defendant failed to perform its duties to commercialize
`plaintiff’s product under a licensing agreement.
`
`Fera Pharmaceuticals LLS v. Akorn Inc. United States District Court, Southern District of
`New York, Case No. 1:12-cv-07694. Retained as the testifying expert on behalf of Fera.
`Authored expert report and provided deposition testimony evaluating damages, including
`diminished asset value, resulting from alleged breach of contract, fraudulent inducement,
`and misappropriation of trade secrets related to Fera’s portfolio of prescription
`ophthalmic anti-infective ointment products. The matter settled on the eve of trial for an
`undisclosed amount.
`
`Served as consulting expert to provide liability and damages analysis for a multinational
`pharmaceutical company in a qui tam case involving potential violations of state law in
`its marketing practices.
`
`Retained as testifying and consulting expert to analyze the economics of a pharmacy
`services contract evaluation and award process for a leading institutional pharmacy in a
`dispute with a large state’s Department of Public Safety and Correctional Services.
`
`Retained as consulting expert by a class of state Medicaid claimants to evaluate the
`state’s application of an econometric model for benefit determination decisions.
`
`CV of Richard Manning, Ph.D.
`
`Page 3
`
`Attachment A-1
`
`Exhibit 2052
`Page 141 of 289
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2001 Page 141
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`CONFIDENTIAL - PROTECTIVE ORDER MATERIAL
`
`

`

`Intellectual Property 
`
`10.
`
`11.
`
`12.
`
`13.
`
`14.
`
`15.
`
`16.
`
`Baxalta Incorporated and Baxalta GmbH v. Genentech, Inc. and Chugai Pharmace3utical
`Co., Ltd. United States District Court, District of Delaware, Case No. 17-509-TBD.
`Submitted rebuttal expert report and testified in deposition. The matter concluded with
`a summary judgment for Genentech.
`
`Purdue Pharma v. Alvogen Pine Brook. United States District Court, District of Delaware,
`Case No. 1:17-cv-00677. Retained as testifying expert to assess the commercial success
`of a prescription drug in a patent infringement litigation related to certain Abbreviated
`New Drug Applications (ANDAs) filed by defendant. Submitted expert reports and
`provided deposition testimony. The matter settled on the verge of trial.
`
`CoreSource v. Quality Healthcare Intermediary. United States District Court, Northern
`District Court of Illinois, Case No. 1:13-cv-05182. Submitted declarations to US Patent
`Trial and Appeals Board on behalf of the petitioner in a patent infringement matter
`involving methods for optimizing healthcare services management. Patent owner
`respondent terminated its claims.
`
`Retained as consulting expert on behalf of defendant in a breach of contract matter
`between biopharmaceutical companies before the International Chamber of Commerce.
`Plaintiff was seeking damages for alleged lost profits related to a joint marketing
`agreement. Provided support to testifying expert in preparing a rebuttal report regarding
`the impact of adoption and pricing of biosimilar products entering the marketplace in
`certain Asian countries.
`
`Served as consultant to a university assessing damages against a consumer products
`company by an unauthorized filing of patents on property owned by the university.
`Submitted a declaration to a federal district court addressing recommended economic
`principles and methodologies for assessing the university’s intellectual property market
`value.
`
`Provided consulting support in an arbitration between large mobile telecommunications
`companies regarding royalties to be paid for standard-essential patents.
`
`Served as consulting expert for a medical device manufacturer in an International Trade
`Commission (ITC) matter to evaluate potential harm to public interest in connection with
`alleged improper importation of surgical devices.
`
`Securities Litigation 
`
`17. Wells Fargo Bank et al. v. Merrimack Pharmaceuticals, Inc. Court of Chancery of the State
`of Delaware. Retained as testifying expert on behalf of plaintiffs. The plaintiffs alleged that
`the company’s asset sale was a sale of “substantially all” of the assets, which was a
`fundamental change, and Merrimack was required to repurchase the convertible notes.
`Submitted primary and rebuttal reports that valued Merrimack’s pipeline of oncology
`drugs and opined that the sale of Merrimack’s sole commercial product constituted a
`fundamental change of the company. Following the exchange of reports, the parties
`settled.
`
`18.
`
`Neogenix Oncology v. Peter Gordon et al. United States District Court, Eastern District of
`New York, Case No. 2:14-cv-04427. Submitted a witness statement regarding the value
`of an early-stage biopharmaceutical company. The parties settled.
`
`CV of Richard Manning, Ph.D.
`
`Page 4
`
`Attachment A-1
`
`Exhibit 2052
`Page 142 of 289
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2001 Page 142
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`CONFIDENTIAL - PROTECTIVE ORDER MATERIAL
`
`

`

`Antitrust and Competition 
`
`19.
`
`20.
`
`Pharmaceutical Solutions, Inc. (VetSource) v. Nevada State Board of Pharmacy et al. United
`States District Court, District of Nevada, Case No. 2:16-cv-171-RFB-VCF. Retained as the
`testifying expert on behalf of VetSource, which sued in federal court in response to a
`cease and desist action that alleged illegal kickbacks. Authored expert report evaluating
`the market for pet medications in Nevada and the VetSource business model to assess
`whether the company competes with other retail pharmacies in this market. The parties
`settled the federal lawsuit on undisclosed terms. VetSource continues to operate in the
`state under its previously existing business model, and the complaint from the Nevada
`Board of Pharmacy was rescinded.
`
`Conducted detailed economic analysis on behalf of Eli Lilly in connection with its $5.4
`billion acquisition of Novartis Animal Health. Both firms were active in developing and
`marketing animal health products, including medications used to treat pets and
`livestock. Team assessed overlaps in several areas, and presented results of its analysis
`to the FTC. The FTC approved the merger after an eight-month investigation, with
`divestiture required in one product area, canine parasiticides.
`
`
`Selected Policy and Business Consulting Experience
` Retained by a multinational pharmaceutical company to develop a tool based on economic
`theory to help the company optimize its participation in price-related contract negotiations
`with foreign purchasers of generic drug products and biosimilars. The tool provides the
`predicted win probability for a given bid and calculates expected profits based on observed
`market factors.
` Retained to provide consulting services to a start-up pharmaceutical manufacturing
`company pursuing opportunities in underserved product spaces in both public and private
`sector markets.
` Retained by a coalition of health insurance companies to assess the costs of compliance
`with proposed federal regulation regarding transparency and provision of information to
`customers.
` Analyzed the prospective impact of the “Cadillac tax” section of the Affordable Care Act on
`employer and employee choices regarding insurance options, healthcare spending, and
`federal revenue. Used the Congressional Budget Office health insurance simulation model
`and predicted that the tax would lead to a lower offer rate of health benefits by employers
`and an increase in overall healthcare spending, and that the tax would have
`disproportionate effects on minority populations.
` Retained as consulting expert for a multinational manufacturer of injectable blood plasma
`derivatives to evaluate the economics of manufacturing and distribution of plasma-based
`medications and the potential impact of regulatory restrictions on certain business
`practices.
` Retained as consulting expert for a global life sciences company to evaluate the economics
`of biosimilar entry in the United States and key international markets. The focus is on
`market penetration and pricing of medicines entering under a new regulatory framework
`for follow-on biologics.
`
`CV of Richard Manning, Ph.D.
`
`Page 5
`
`Attachment A-1
`
`Exhibit 2052
`Page 143 of 289
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2001 Page 143
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`CONFIDENTIAL - PROTECTIVE ORDER MATERIAL
`
`

`

` Retained by a leading healthcare company to prepare a report analyzing the economics of
`the market for blood plasma products in response to changing demand and cost conditions.
` Retained by a multinational life sciences company to analyze the market for oncology
`products with respect to the sustainability of current and projected future trends in pricing,
`utilization, and reimbursement.
` Retained by a multinational life sciences and healthcare company to analyze links between
`health status and economic well-being across countries and over time.
` Prepared a report for research-based pharmaceutical and biotechnology companies
`evaluating potential compliance costs resulting from Affordable Care Act price reporting
`requirements to government agencies.
` Performed an economic impact analysis of research and development activities for a leading
`non-profit stem cell foundation, working with scientists to evaluate programs and assess
`impact on future economic activity.
`
`
`Selected Corporate Experience
` Led teams in the assessment of emerging strategic challenges facing a major
`biopharmaceutical company in both human and animal health businesses related to
`industry pricing, marketing and other business practices, managed care and government
`payor access restrictions, intellectual property protection, litigation threats, healthcare
`reform proposals, etc.
` Led teams working on mergers and acquisitions analysis for both human and animal health
`divisions of biopharmaceutical companies, undertaking commercial due diligence,
`evaluating target companies and market conditions, and providing economic analysis of
`divestiture options in response to regulatory concerns.
` Worked with leadership of disease management subsidiary of major biopharmaceutical
`company overseeing studies of health benefits design on issues including medication
`adherence, cost, and medical outcomes.
` Participated in an executive-level initiative on individualized medicine focused on
`identifying and evaluating future opportunities in the business of human genetics as it
`related to the development of gene-based diagnostics and therapeutics.
` Explored and evaluated various strategic business opportunities for a major medical center
`involved in research and development of gene-based diagnostics.
` Served as company spokesperson on major economic issues and as the company
`representative on key industry trade organization teams responsible for conducting
`research projects that addressed the value of innovation, pricing and reimbursement
`threats, intellectual property protection, international trade-related pricing challenges, etc.
` Developed and provided training on economics of drug discovery and development for
`research scientists at a global biopharmaceutical company.
`
`CV of Richard Manning, Ph.D.
`
`Page 6
`
`Attachment A-1
`
`Exhibit 2052
`Page 144 of 289
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2001 Page 144
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`CONFIDENTIAL - PROTECTIVE ORDER MATERIAL
`
`

`

`Journal Articles
`“Comment on ‘Market Exclusivity for Drugs with Multiple Orphan Approvals (1982–2017) and
`Associated Budget Impact in the US.’” PharmacoEconomics. 38, 1373–1374 (2020).
`https://doi.org/10.1007/s40273-020-00975-7
`
`“The Clinical and Economic Impact of the Early Detection and Diagnosis of Cancer,” with Peter
`J. Deckers, Tricia Laursen, Stacey Worthy, and Shruti Kulkarni, Health Law & Policy Brief XIV,
`no. 2 (2020): 1–20.
`“Prices and Related Controversies in the Biopharmaceutical Industry,” International Journal of
`the Economics of Business 25, no. 1 (2018): 157–66.
`
`“Vaccination and GDP Growth Rates: Exploring the Links in a Conditional Convergence
`Framework,” with Neal A. Masia, Jonathan Smerling, Tendayi Kapfidze, and Mark Showalter,
`World Development 103 (2018): 88–99.
`
`“Risk-based Decision Making and Ethical Considerations in Donor Compensation for Plasma-
`derived Medicinal Products,” with Mark Skinner, Ann Hedlund Hoppe, Henry Grabowski, Raffi
`Tachdjian, James Crone, and Stuart Youngner, Transfusion (2016): 1–6.
`
`“An Economic Analysis of Global Policy Proposals to Prohibit Compensation of Blood Plasma
`Donors,” with Henry Grabowski, International Journal of the Economics of Business 23, no. 2
`(2016): 149–66.
`
`“Similar Products at Different Prices: Can Biopharmaceutical Companies Segment Markets?”
`with Christopher Stomberg, Benjamin Scher, Kathleen Twigg, and Andrew Huson, International
`Journal of the Economics of Business 22, no. 2 (2015): 231–44.
`
`“Pharmaceutical Risk Sharing Agreements,” with Joseph Cook and John Vernon,
`Pharmacoeconomics 26, no. 7 (2008): 551–56.
`
`“Special Issue on Economics of Pharmaceutical Industry,” co-editor with John Vernon,
`Managerial and Decision Economics 28, no. 4–5 (2007): 229–522.
`
`“The Benefits of Switching Smoking Cessation Drugs to OTC,” with Teh-wei Hu, Hai-Yen Sung,
`Theodore E. Keeler, Martin Marciniak, and Alison Keith, Health Economics 11, no. 5 (2002):
`389–402.
`“Economic Impact of Product Liability in US Prescription Drug Markets,” International Business
`Lawyer 29, no. 3 (2001): 104–09.
`
`“Have Changing Liability Rules Compensated Workers Twice for Occupational Hazards?
`Earnings Premiums and Cancer Risk,” with John R. Lott, Jr., Journal of Legal Studies 29
`(2000): 99–130.
`
`“The Length of Time Necessary to Break Even after Converting to Digital Mammography,” with
`Mark D. Hiatt and J. Jeffrey Carr, Journal of Telemedicine and Telecare 6, no. 4 (2000): 222–24.
`
`“Products Liability and Prescription Drug Prices in Canada and the United States,” Journal of
`Law and Economics 40 (1997): 203–44.
`
`“How Term Limits Enhance the Expression of Democratic Preferences,” with Einer Elhauge and
`John R. Lott, Jr., Supreme Court Economic Review 5 (1997): 59–80.
`
`“Is the Insurance Aspect of Producer Liability Valued by Consumers? Liability Changes and
`Childhood Vaccine Consumption,” Journal of Risk and Uncertainty 12 (1996): 343–58.
`
`CV of Richard Manning, Ph.D.
`
`Page 7
`
`Attachment A-1
`
`Exhibit 2052
`Page 145 of 289
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2001 Page 145
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`CONFIDENTIAL - PROTECTIVE ORDER MATERIAL
`
`

`

`“Logit Regressions with Continuous Dependent Variables Measured with Error,” Applied
`Economics Letters 3 (1996): 183–84.
`
`“Changing Rules in Tort Law and the Market for Childhood Vaccines,” Journal of Law and
`Economics 37 (1994): 247–75.
`
`
`Corporate Publications
`Economic Realities in Health Care Policy, monograph series, Editor, Pfizer Inc., 1998–2005.
`
`
`
`“The Competitive Advantage of a Healthy Workforce,” Editor, with Alison Keith, 1998.
`“Pharmaceutical Prices: What’s Missing from the Public Discussion,” with Alison Keith,
`2000.
`“Prescription Drug Advertising: Empowering Consumers through Information,” 2002.
`“Pharmaceutical Innovation: Lowering the Price of Good Health,” 2002.
`“Pharmaceutical Prices: What’s Missing from the Public Discussion, Updated,” with Neal
`Masia, 2002.
`“Pharmaceutical Marketing and Promotion: Creating Access to Innovation,” with Neal
`Masia, 2003.
`“Who Invents New Medicines?” Editor, with Neal Masia, 2005.
`
`
`
`
`
`
`
`
`
`Other Publications
`“Public Comment to Multilateral Pharmaceutical Merger Task Force” with Kira Stearns, Kyle
`Kost, and Richard Brady, June 2021, available at
`https://www.regulations.gov/comment/FTC-2021-0025-0038.
`“Risks In Moving Too Quickly, Or Slowly, On COVID-19 Vaccine” Law360, December 2020,
`available at https://www.law360.com/articles/1336937.
`
`“An Integrated Supply Chain: A White Paper on Addressing Essential Medicine Shortages” with
`Anthony Flammia, Kristina McKean, and Patricia Watson, August 2020, available at
`https://www.phlow-usa.com/wp-content/uploads/Phlow_SAPIR_Whitepaper_091020.pdf
`“Economic Profitability of the Biopharmaceutical Industry: 2020 Update,” with Saurav Karki,
`Policy Brief, May 2020, available at https://www.bateswhite.com/newsroom-insight-Economic-
`Profitability-Biopharmaceutical-Industry-2020-update.html.
`“Estimating the Burden of the Proposed Transparency in Coverage Rule,” with Arun Sharma
`and Zachary Mozenter, Bates White Economic Consulting White Paper, January 2020,
`available at
`https://www.bateswhite.com/media/publication/183_Estimating%20Burden%20of%20Propos
`ed%20TCR.pdf.
`“Policies to Reduce Prices of Prescription Medicines,” Policy Brief, September 2019, available at
`https://www.bateswhite.com/media/publication/181_Policy%20Brief%20on%20price%20cont
`rol%20measures.2019.09.18.pdf.
`“The International Pricing Index for Medicare Part B Drugs,” Policy Brief, February 2019,
`available at
`
`CV of Richard Manning, Ph.D.
`
`Page 8
`
`Attachment A-1
`
`Exhibit 2052
`Page 146 of 289
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2001 Page 146
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`CONFIDENTIAL - PROTECTIVE ORDER MATERIAL
`
`

`

`https://www.bateswhite.com/media/publication/170_International%20Pricing%20Index%20fo
`r%20Medicare%20Part%20B%20Drugs.pdf.
`“Continuous Manufacturing in Pharmaceuticals: Economic and Policy Issues,” with Richard
`Sciacca, October 2018, available at
`https://www.bateswhite.com/media/publication/171_Continuous%20Manufacturing.pdf.
`“Economic Profitability of the Biopharmaceutical Industry,” with Saurav Karki, Policy Brief,
`September 2018, available at
`https://www.bateswhite.com/media/publication/167_Economic%20profitability%20of%
`20the%20drug%20industry.pdf.
`“Commentary on Biotech vs. Pharma Investments,” Carlson School of Management, Medical
`Industry Leadership Institute Exchange 19, Summer 2018.
`“Key Economic and Value Considerations in the US Market for Plasma Protein Therapies,” with
`Henry Grabowski, February 2018.
`“Biosimilar Coding and Reimbursement under Medicare Part B,” with Christopher Stomberg
`and Ben Wolfert, November 2017.
`“Poorly Executed Analyses of Drug Research and Development Is Useless.” The Hill. September
`29, 2017, available at http://thehill.com/opinion/healthcare/353072-poorly-executed-
`analyses-of-pharmaceutical-rd-is -useless?rnd=1506695357.
`“Penalizing Generic Drugs with the CPI Rebate Will Reduce Competition and Increase the
`Likelihood of Drug Shortages,” with Fred Selck, September 2017, available at
`https://www.accessiblemeds.org/sites/default/files/2017-09/Bates-White-White-Paper-
`Report-CPI-Penalty-09 -12-2017.pdf.
`“Drug Prices and Medical Innovation: A Response to Yu, Helms, and Bach,” with Henry
`Grabowski, Health Affairs Blog, June 2, 2017, available at
`http://healthaffairs.org/blog/2017/06/02/drug-prices-and-medical -innovation-a-response-
`to-yu-helms-and-bach/.
`“Oncology Product Sales and Patent Expiration: A Policy Brief,” with Fred Selck, June 2017,
`available at http://www.bateswhite.com/insight-173.html.
`“The Role of Value and Cost in Prescription Drug Pricing,” Law360, September 27, 2016.
`“Tax Inversions: How Do Financial Metrics of Foreign Acquisitions Compare?” with Richard
`Sciacca and Alan Alford, Apr. 6, 2016.
`“Tax Inversions: A Preliminary Review of Company Financial Data,” with Richard Sciacca and
`Alan Alford, Jan 12, 2016.
`“Our Best Shot: Expanding Prevention through Vaccination in Older Adults,” with Fred Selck
`and Kathleen Chandler, July 29, 2015.
`
`Recent Presentations and Panels
`
`“15th Meeting of the American College of Business Court Judges, “Pharmaceutical
`Regulation: Lessons and Enduring Impacts of Deregulatory Incentives Embraced
`During a Pandemic,” Panel discussion, George Mason University Antonin Scalia Law
`School Law and Economics Center, Savanah, GA, October 30, 2020.
` Global Plasma Summit 2020, “The Plasma Industry and Possible Effects of the COVID
`Pandemic,” Presenter, virtual conference, October 30, 2020
`
`CV of Richard Manning, Ph.D.
`
`Page 9
`
`Attachment A-1
`
`Exhibit 2052
`Page 147 of 289
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2001 Page 147
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`CONFIDENTIAL - PROTECTIVE ORDER MATERIAL
`
`

`

` Promoting Innovation in the Life Science Sector and Supporting Pro-Competitive
`Collaborations: The Role of Intellectual Property, “Academics’ and Economists’ Views on
`Collaboration and Competition,” Joint DOJ/USPTO Antitrust Webinar panelist,
`September 24, 2020
` Meeting of the Association of Blood Service of Ukraine and the Ukrainian Society of
`Immunology, Allergology and Immunorehabilitation, “Assessing Value for Plasma
`Protein Therapies,” Presentation, Kiev, Ukraine, September 19, 2019
` 8th Annual American Society of Health Economics meeting, “Setting Drug Prices in
`Medicare: Toward a Competitive Market?” Policy Roundtable moderator, Washington,
`DC, June 24, 2019.
` 2019 Plasma Protein Therapeutics Association, Plasma Forum, “Assessing Value for
`Plasma Protein Therapies,” Panel discussion, Reston, VA, June 18, 2019.
` Symposium on the Legal, Economic, and Regulatory Environment of the
`Pharmaceutical Industry, “Who Really Pays for Drugs and How Much? Marketing,
`Pricing, and Transparency,” Panel discussion, George Mason University Antonin Scalia
`Law School, Arlington, VA, April 15, 2019.
` 15th Annual Symposium of the Journal of Law, Economics, and Policy: Health Care
`Cost, Quality, and Transparency, “Why Do Drugs Cost so Much? What (If Anything)
`Should We Do About It?” Panel discussion, George Mason University Antonin Scalia
`Law School, Arlington, VA, November 16, 2018.
` Pneumococcal Vaccination Pharmacoeconomic Summit, “Childhood Vaccination and
`Economic Growth,” Presentation, Dubai UAE, February 24, 2018.
` George Mason University Center for the Protection of Intellectual Property Summer
`Institute, “The Challenges of Encouraging Long-Term Innovation,” Panel discussion,
`Beaver Creek, CO, July 12, 2017.
`International Health Economics Association, Boston 2017 Congress, “Global Spending
`Patterns for Oncology Medications,” Presentation, Boston, July 9, 2017.
` George Mason University Center for the Protection of Intellectual Property Fourth
`Annual Fall Conference, “Assessing the Economic Case for Patents,” Panel discussion,
`Arlington, VA, October 7, 2016.
` AcademyHealth Annual Research Meeting, “Building a Successful HSR Career Outside
`the ‘Ivory Tower,’” Panel discussion, Boston, MA, June 27, 2016.
` Sidley Austin’s Global Drug Pricing Conference, “Options for Responding to Price
`Scrutiny, including Value Based Contracting,” Washington, DC, April 20, 2016.Bates
`White Life Sciences Symposium, “Anti-Kickback Statute,” Panel moderator,
`Washington, DC, June 8, 2015.
` George Mason University Center for the Protection of Intellectual Property Roundtable,
`“Patented Innovation in the Pharmaceutical and Biotech Industries,” Hilton Head, SC,
`May 28–29, 2015.
` George Mason University Attorneys General Education Program, “Pharmaceutical
`Marketing: Economic and Legal Issues,” Arlington, VA, March 26, 2015.
` Bates White Life Sciences Symposium, “Oncology Case Study,” Washington, DC, June
`13, 2014.
` Bates White Life Sciences Symposium, “Litigation Landscape since Last Year’s Supreme
`Court Decision in FTC v. Actavis,” Panelist, Washington, DC, June 12, 2014.
`
`
`
`CV of Richard Manning, Ph.D.
`
`Page 10
`
`Attachment A-1
`
`Exhibit 2052
`Page 148 of 289
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2001 Page 148
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`CONFIDENTIAL - PROTECTIVE ORDER MATERIAL
`
`

`

`
`
` Bates White Healthcare & Life Sciences Symposium, “Co-pay Coupons Case Study,”
`Washington, DC, June 10, 2013.
`Indian Institute of Management Bangalore Roundtable, “Ethical Issues in the Health
`Care Sector in India,” March 2013.
` ACI’s West Coast Edition Paragraph IV Disputes Conference, “Damages Analysis,” San
`Francisco, CA, December 5, 2012.
` McGuireWoods’ 4th Annual Medical Device and Life Sciences Conference, “Key
`Economic and Legal Issues in Prescription Drug Marketing,” Chicago, IL, November 8,
`2012.
` George Mason University Attorneys General Education Program, “Marketing and
`Advertising of Prescription Drugs: An Economic Perspective,” Arlington, VA, May 3,
`2012.
` Medical Industry Leadership Institute, Carlson School of Management, University of
`Minnesota, Panel discussion, May 2011.
`PhRMA Asia Pacific Meeting, Panel discussion chair, Singapore, January 2011.
`Incisive Media 7th Annual Healthcare M&A and Business Development Conference,
`Presentation, Atlanta, GA, September 2009.
`The Deal Healthcare Dealmaking Symposium, Presentation, New York, NY, March 2009.
`
` Drug Industry Association Annual Meeting, Presentation, 2008.
`
`
`
`
`
`Professional Activities
` Advisory Board, Medical Industry Leadership Institute, Carlson School of Management,
`University of Minnesota
` Business Research Advisory Committee Member and Price Index Committee Chair, US
`Bureau of Labor Statistics
` Advisory Board, Rutgers Business School, Lerner Center for Pharmaceutical Management
`Founding Member and Advisory Board, Center for Value Based Insurance Design,
`University of Michigan
` Corporate Council Member, Brookings Institution
` Editorial Board, Managerial and Decision Economics
` Ad hoc referee for International Journal of the Economics of Business, Journal of Political
`Economy, Journal of Law and Economics, Journal of Legal Studies, Journal of Industrial
`Economics, Health Affairs, Forum for Health Economics and Policy, The Social Science
`Journal
`
`
`
`PROFESSIONAL ASSOCIATIONS
` American Economic Association
` American Society of Health Economists
` Economic Club of New York
`
`CV of Richard Manning, Ph.D.
`
`Page 11
`
`Attachment A-1
`
`Exhibit 2052
`Page 149 of 289
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2001 Page 149
`Samsung Bi